1. Kim A, Strober B. Janus Kinase Inhibitors. Biologic and Systemic Agents in Dermatology: Springer; 2018. P. 187-98. [
DOI:10.1007/978-3-319-66884-0_19]
2. Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell PH, et. al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A. 2006;103(3):654-9. [
DOI:10.1073/pnas.0508423103] [
PMID] [
PMCID]
3. Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 2014;123(13):2075-83. [
DOI:10.1182/blood-2014-01-547760] [
PMID] [
PMCID]
4. Ghafari H, Karimzadeh P, Chahardouli B, Alimoghdam K, Ghavamzadeh A, Dargahi H, et al. Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR. Journal of Payavard Salamat.2009;3(2):94-101.
5. Hubbard SR. Mechanistic insights into Regulation of JAK2 Tyrosine Kinase. Front Endocrinol (Lausanne). 2018;8:361. [
DOI:10.3389/fendo.2017.00361] [
PMID] [
PMCID]
6. Ayatollahi H, Sadeghian MH, Keramati MR, Karimiani EG, Jafarian AH, Shirdel A, et al. JAK2 V617F Mutation in Adult T Cell Leukemia-Lymphoma. Indian J Hematol Blood Transfus. 2016;32(4):437-441. [
DOI:10.1007/s12288-015-0620-4] [
PMID] [
PMCID]
7. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol. 2000; 20(10):3387-3395. [
DOI:10.1128/.20.10.3387-3395.2000] [
PMID] [
PMCID]
8. Williams JJ, Munro K, Palmer TM. Role of Ubiquitylation in Controlling Suppressor of Cytokine Signalling 3(SOCS3) Function and Expression. Cells. 2014;3(2):546-562. [
DOI:10.3390/cells3020546] [
PMID] [
PMCID]
9. Ebid GT, Ghareeb M, Salaheldin O, Kamel MM. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. Int J Clin Exp Pathol. 2015;8(9):11555-11559.
10. Bagheri M, Abdirad I, Maleki D, Eyshi A, Valizadeh N. Acquired mutation of the tyrosine kinase JAK2 V617F in the ABL-BCR-negative chronic myeloproliferative diseases in a population of west Azerbaijan province, Iran. Journal of Isfahan Medical School. 2018;35(459):1785-1791.
11. Langabeer SE. The JAK2 V617F mutation in isolated neutropenia. EXCLI J. 2018;17:1-2. [
DOI:10.1016/j.hemonc.2016.08.006] [
PMID]
12. Barosi G, Mesa R, Thiele J, Cervantes F, Campbell P, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemiamyelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-8. [
DOI:10.1038/sj.leu.2404914] [
PMID]
13. Neet K, Hunter T. Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells. 1996;1(2):147-69. [
DOI:10.1046/j.1365-2443.1996.d01-234.x] [
PMID]